34 results
Thumbnail

D2.394 - Mycoplasma-Induced Drug Hypersensitivity: Rare Complication or Coincidence?

Thumbnail

D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients

Thumbnail

D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity

Thumbnail

D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children

Thumbnail

D2.403 - When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem

Thumbnail

D2.405 - UnDRESSing AGEP and Revealing Erythema Multiforme

Thumbnail

D2.406 - Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges

Thumbnail

D2.393 - Aspirin hypersensitivity and desensitization-Sense and sensibility

Thumbnail

D2.396 - Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol

Thumbnail

D2.397 - Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case

Thumbnail

D2.398 - Ibuprofen Challenge or Desensitisation in Myo-Pericardial Disease: A Case Series

Thumbnail

D2.400 - Vitamin Hypersensitivity in the Era of Intravenous ‘Cocktails’: Diagnostic Pitfalls and Clinical Consequences

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort